Measles virus (MV), a member of the family Paramyxoviridae and an exclusively human pathogen, is among the most infectious viruses. A progressive fatal neurodegenerative complication, subacute sclerosing panencephalitis (SSPE), occurs during persistent MV infection of the CNS and is associated with biased hypermutations of the viral genome. The observed hypermutations of A-to-G are consistent with conversions catalyzed by the adenosine deaminase acting on RNA (ADAR1). To evaluate the role of ADAR1 in MV infection, we selectively disrupted expression of the IFN-inducible p150 ADAR1 isoform and found it caused embryonic lethality at embryo day (E) 11-E12. We therefore generated p150-deficient and WT mouse embryo fibroblast (MEF) cells stably expressing the MV receptor signaling lymphocyte activation molecule (SLAM or CD150). The p150 −/− but not WT MEF cells displayed extensive syncytium formation and cytopathic effect (CPE) following infection with MV, consistent with an anti-MV role of the p150 isoform of ADAR1. MV titers were 3 to 4 log higher in p150 −/− cells compared with WT cells at 21 h postinfection, and restoration of ADAR1 in p150 −/− cells prevented MV cytopathology. In contrast to infection with MV, p150 disruption had no effect on vesicular stomatitis virus, reovirus, or lymphocytic choriomeningitis virus replication but protected against CPE resulting from infection with Newcastle disease virus, Sendai virus, canine distemper virus, and influenza A virus. Thus, ADAR1 is a restriction factor in the replication of paramyxoviruses and orthomyxoviruses. M easles virus (MV), a member of the family Paramyxoviridae, infects more than 10 million persons worldwide each year, resulting in several hundred thousand deaths (1, 2). A serious complication is the persistent infection of the CNS known as subacute sclerosing panencephalitis (SSPE) that occurs at a frequency of 4-11 cases per 100,000 cases of MV infection. SSPE is a progressive fatal neurodegenerative disease with characteristic features of replication of MV in neurons in the presence of high titers of MV antibodies, modest infiltration of T and B cells into the CNS, and replication of defective MV in the CNS with biased mutation of U-to-C and A-to-G in the viral genome (3-5). These hypermutations occur primarily in the matrix (M) gene but are also observed to a lesser extent in the fusion (F) and hemagglutinin (H) genes (3, 4). A transgenic mouse model that expresses the human MV receptor CD46 recapitulates all the features of SSPE on infection with MV, with biased hypermutations of U-to-C and A-to-G accounting for more than 95% of point mutations in the M gene (3, 4, 6) . Interestingly, these biased hypermutations play a direct role in the pathogenesis of SSPE by facilitating a significant prolongation of MV persistence within the CNS, as opposed to mere accumulation as a result of persistent infection (7). In support of a direct role of M gene hypermutations in the establishment of SSPE, MV generated by reverse genetics and containing a hypermutated M gene caused a significant prolongation of the viral persistent state when used to infect the CD46 transgenic mice compared with MV containing a normal M gene (7). Although this provided evidence for a biological importance of biased hypermutations of the M gene in the establishment of persistent infection, neither the mechanism by which mutations in the MV genome arise nor the effect of adenosine deaminase acting on RNA (ADAR1) on MV replication was known. Because of the uniformity of mutations observed (4), it has been postulated that the biased hypermutations are likely the result of an enzymatic activity, with an attractive candidate enzyme being ADAR1.
M easles virus (MV), a member of the family Paramyxoviridae, infects more than 10 million persons worldwide each year, resulting in several hundred thousand deaths (1, 2) . A serious complication is the persistent infection of the CNS known as subacute sclerosing panencephalitis (SSPE) that occurs at a frequency of 4-11 cases per 100,000 cases of MV infection. SSPE is a progressive fatal neurodegenerative disease with characteristic features of replication of MV in neurons in the presence of high titers of MV antibodies, modest infiltration of T and B cells into the CNS, and replication of defective MV in the CNS with biased mutation of U-to-C and A-to-G in the viral genome (3) (4) (5) . These hypermutations occur primarily in the matrix (M) gene but are also observed to a lesser extent in the fusion (F) and hemagglutinin (H) genes (3, 4) . A transgenic mouse model that expresses the human MV receptor CD46 recapitulates all the features of SSPE on infection with MV, with biased hypermutations of U-to-C and A-to-G accounting for more than 95% of point mutations in the M gene (3, 4, 6) . Interestingly, these biased hypermutations play a direct role in the pathogenesis of SSPE by facilitating a significant prolongation of MV persistence within the CNS, as opposed to mere accumulation as a result of persistent infection (7) . In support of a direct role of M gene hypermutations in the establishment of SSPE, MV generated by reverse genetics and containing a hypermutated M gene caused a significant prolongation of the viral persistent state when used to infect the CD46 transgenic mice compared with MV containing a normal M gene (7) . Although this provided evidence for a biological importance of biased hypermutations of the M gene in the establishment of persistent infection, neither the mechanism by which mutations in the MV genome arise nor the effect of adenosine deaminase acting on RNA (ADAR1) on MV replication was known. Because of the uniformity of mutations observed (4) , it has been postulated that the biased hypermutations are likely the result of an enzymatic activity, with an attractive candidate enzyme being ADAR1.
ADAR1 catalyzes the conversion of adenosine (A) to inosine (I) on double-stranded RNA substrates, thereby introducing Ato-G mutations because I is recognized as G by the translation and viral RNA-dependent RNA transcription and replication machineries (8) (9) (10) . Thus, A-to-I editing of both cellular and viral RNA substrates has the capacity to alter coding capacity and RNA structure (9) . ADAR1 expression is driven by three promoters, one of which is inducible by IFN. The IFN-inducible form of ADAR1 is a 150-kDa protein referred to as p150 that localizes to both the cytoplasm and the nucleus (11), whereas a smaller constitutively expressed form of ADAR1 referred to as p110 is localized predominantly in the nucleus. Several features of the p150 protein make it a likely candidate enzyme responsible for generating biased hypermutations of the M gene associated with SSPE, including its presence in the cytoplasm, the site of MV replication, and its induction by IFN, a cytokine induced in response to viral infection (12) . In addition, induction of ADAR1 in the CNS as a result of viral infection likely contributes to neuronal cell dysfunction, because ADAR1 is essential for glutamate and serotonin receptor editing (3, 9, 13) .
Nevertheless, whether the p150 isoform of ADAR1 had a direct antiviral function remained unknown. Earlier gene disruptions of ADAR1 eliminated expression of both the p110 and p150 isoforms, resulting in embryonic lethality (14, 15) . Here, we report that selective disruption of expression of the IFNinducible p150 isoform of ADAR1 was embryonic-lethal. Further, we recovered mouse embryo fibroblast (MEF) cells homozygous and heterozygous for deletion of p150 and show that the p150 isoform of ADAR1 inhibits MV replication as well as protecting against infection with representative viruses of the paramyxovirus and orthomyxovirus families.
Results
Disruption of the Gene Encoding the p150 Isoform of ADAR1 Results in Embryonic Lethality. We generated a targeted gene disruption that selectively abolishes expression of only p150 and leaves ex-pression of p110 intact. A targeting vector was constructed containing Adar1 genomic sequences to disrupt the IFN-inducible P A promoter and its associated IFN-inducible exon 1A region specifically (16, 17) (Fig. 1A) . Successful targeting of Adar1 p150 was confirmed by PCR, with the disrupted and WT alleles yielding the predicted bands of 1,129 and 384 bp, respectively (Fig. 1B) . Although live embryos that were either WT or heterozygous for the disrupted Adar1 p150 allele were readily observed, no live embryos homozygous for the Adar1 p150 gene disruption were recovered. Consistent with the conclusion that specific targeting of the p150 isoform of ADAR1 resulted in embryonic lethality, no live animals that possessed both copies of the disrupted allele were born on intercrossing Adar1 p150+/− heterozygotes ( Fig. 1 B  and C) . By contrast, WT Adar1 p150+/+ and heterozygous Adar1 p150+/− animals were born at the approximate expected Mendelian frequencies. Moreover, Adar1 p150−/− embryos displayed abnormal morphology compared with their WT and heterozygous counterparts (Fig. 1D) . Thus, embryonic lethality occurred only with deletion of both copies of the Adar1 p150 gene. Lethality at embryo day (E) 11 to E12 of development was similar to previously described Adar1 gene disruptions that targeted expression of both p110 and p150 (14, 15) . (Fig. 1E) . By contrast, the exon 1A-containing transcript that encodes the p150 protein was only detectable in WT and p150 +/− MEF cells but not in p150 −/− MEF cells even on treatment with IFN-α. These results confirm selective disruption of p150 expression while leaving expression of p110 intact.
Because rodent cells are not permissive to MV infection as a result of the lack of a virus receptor, we generated WT, p150 +/− , and p150 −/− MEF cells expressing the MV receptor (CD150) fused to GFP at its C terminus (hSLAM-GFP). Functionality of the fusion protein as evidenced by syncytium formation following infection with MV was confirmed by introduction of hSLAM-GFP into nonpermissive BHK-21 cells (Fig. S1A) . We next transiently transfected hSLAM-GFP into WT, p150 +/− , or p150 −/− MEF cells. On infection with MV, only p150 −/− MEF cells that expressed hSLAM-GFP but not vector control-transfected cells displayed significant cytopathic effect (CPE) (Fig.   S1B , data not shown). By contrast, neither WT nor p150 +/− MEF cells that expressed the hSLAM-GFP fusion protein displayed CPE (Fig. S1B) . Thus, development of CPE was dependent on both expression of human SLAM and infection with MV.
To evaluate the effect of MV infection in p150 −/− MEF cells quantitatively, we used a lentiviral vector system to generate MEF cells that stably expressed hSLAM-GFP. WT and p150 −/− MEF cells showed similar GFP expression and equivalent high transduction efficiencies (98% or more) when transduced with GFP control vectors (Fig. S2 A and B) . Similar to results obtained with GFP control vectors, comparable expression of the hSLAM-GFP fusion protein was seen in both WT and p150 −/− MEF cells following lentiviral vector transduction (Fig. S2C) . Importantly, although fluorescence intensity of the hSLAM-GFP fusion protein was lower than that seen for cytoplasmic GFP, equivalent expression of hSLAM-GFP was seen by flow cytometry in WT and p150 −/− MEF cells (Fig. S2D ). Having established MEF cells stably expressing hSLAM-GFP or GFP as a control, WT and p150 −/− MEF cells were infected with MV and observed for development of CPE at various time points postinfection, including at 21, 31, and 45 h. As shown in Fig. 2A , at 21 h postinfection, extensive CPE, including formation of syncytia, developed only in p150 −/− MEF cells that stably expressed hSLAM-GFP but not GFP as a control. Likewise, no CPE was detectable in infected WT cells that expressed either GFP or the hSLAM-GFP fusion protein at 21 h postinfection. The differences observed in development of CPE between WT and p150 −/− MEF cells following infection with MV correlated with viral titers obtained at this time point, with 3-to 4-log higher titers seen in p150 −/− MEF cells compared with WT cells (Table  1) control cells expressing GFP did not display CPE and were comparable in appearance to uninfected cells (Fig. 2) . Similar results were obtained when infections were carried out at a multiplicity of infection (MOI) of 0.8 pfu/cell as shown in Fig −/− MEF cells (Fig. 3) . For all these viruses, infection of p150 −/− MEF cells resulted in development of complete CPE as indicated by destruction of the cell monolayer. By contrast, no CPE was observed in uninfected p150
−/− MEF cells or when WT MEF cells were infected. Furthermore, reconstitution of p150 −/− MEF cells with a lentiviral vector delivering murine ADAR1 but not with an empty control lentiviral vector completely protected from development of CPE. Similar results were seen when infections were carried out with the Onderstepoort vaccine strain of CDV, although protection from CPE in p150-reconstituted cells was partial and more variable than that seen for the wild strain of CDV. Taken together, these results indicate a general protective role of the p150 isoform of ADAR1 against infection with paramyxoviruses. In contrast to infection with MV, NDV, SeV, CDV, and influenza A virus, no significant differences were seen at 8, 12, and 24 h postinfection when WT, p150 +/− , and p150 −/− MEF cells were infected with the clone 13 strain of LCMV, as indicated by the comparable presence of viral antigen (Fig. 4B) . In support of this finding, LCMV produced comparable amounts of virus in supernatants from infected WT, p150 +/− , and p150 −/− MEF cells (data not shown). We next performed single-cycle yield analyses of VSV (Fig. 4C) and reovirus (Fig. 4D ) in both untreated and IFN-treated WT, p150 +/− , and p150 −/− MEF cells. Although single-cycle yields of VSV and reovirus were reduced, as expected, by treatment with IFN, no significant differences were seen in virus yields from WT, p150 +/− , and p150 −/− MEF cells.
Discussion
In this paper, we make three observations. First, disruption of the p150 isoform of ADAR1 itself, although maintaining expression of the p110 isoform, is sufficient to cause lethality in Infections were carried out at an MOI of 0.8 pfu/cell, and titers were determined in combined cells and supernatants at the indicated times postinfection (pi). Results are from a representative experiment. With the exception of 0 h postinfection, titers were obtained from duplicate samples.
embryos at E11 to E12. Second, the p150 isoform of ADAR1 is a restriction factor that inhibits MV as well as NDV, SeV, CDV, and WSN influenza virus replication and virus-induced cytotoxicity. Third, the p150 isoform of ADAR1 does not inhibit the replication of LCMV, VSV, or reovirus.
Previous targeted disruptions of Adar1 that involved deletions within the exon 2-15 region and eliminated expression of both the p110 and p150 isoforms of ADAR1 resulted in embryonic lethality (14, 15, 18) . To circumvent the embryonic lethality associated with simultaneous disruption of p110 and p150, we specifically targeted the promoter and exon 1A region of the p150 isoform of ADAR1 while leaving expression of p110 intact. Selective disruption of p150 alone resulted in embryonic lethality at E11 to E12, similar to the time point of embryonic lethality seen previously with disruption of p110 and p150 (14, 15) . These results indicate that the p150 isoform of ADAR1 plays a critically important but not previously recognized role in embryonic development. Furthermore, our results raise the possibility that embryonic lethality seen in previously described Adar1 gene disruptions may have resulted primarily from ablation of p150 expression.
Our ability to generate MEF cells selectively deficient in the IFN-inducible p150 isoform of ADAR1 allowed us to examine a direct role of p150 in MV replication. We found that loss of p150 resulted in higher replication of MV by 21 h postinfection and extensive CPE at all times postinfection. CPE was either absent or minimal in WT MEF cells infected with MV, highlighting the susceptibility of p150 −/− MEF cells to MV infection. Reconstitution of p150 −/− MEF cells with murine ADAR1 firmly established a role of the p150 isoform of ADAR1 in MV infection, as seen by protection from CPE in p150-reconstituted cells. These results demonstrate an antiviral function of the p150 isoform of ADAR1. The delay in production of infectious progeny in WT MEF cells compared with p150
−/− MEF cells may reflect viral adaptation to overcome an intact host antiviral response or incomplete inhibition of viral replication by p150 during a single infection cycle. One implication of our results is that p150 induced by IFN produced during MV infection exerts its antiviral function; however, in SSPE, it allows the infection to be prolonged, likely as a result of its editing activity generating hypermutations (3-7). Our current inability to generate ADAR1 p150 KO mice precludes us from directly testing the role of ADAR1 in vivo in generating biased hypermutations in MV infection.
Our results of increased MV-induced CPE obtained with p150 −/− MEF cells are similar to those of previous studies that examined the role of ADAR1 in MV replication using a shRNA knockdown strategy that stably diminished expression of both the p110 and p150 isoforms (19) . In contrast to our results with MEF cells genetically deficient in p150, however, the shRNA knockdown did not restrict MV replication (19) . The differences between these observations are likely explained by only a partial knockdown of p150 obtained with shRNA (19) compared with complete absence of p150 obtained by genetic ablation or by the different virus strains used (Edmonston, recombinant Moraten). Neither the overexpression nor the knockdown of ADAR1 affected VSV replication in the absence of IFN treatment (20) , similar to our findings with p150 −/− MEFs described herein. Our studies importantly show that the p150 isoform of ADAR1 protects against infection with members of the Paramyxoviridae family in addition to MV, including NDV, SeV, and CDV. For each of these viruses, complete protection from virusinduced CPE was seen in p150 −/− MEF cells reconstituted with murine p150 compared with p150 −/− control cells. Thus, p150 likely plays an important role in the replication of members of the Paramyxoviridae family in general. ADAR1 p150 is the only known ADAR that is found in the cytoplasm, where members of the Paramyxoviridae family of viruses replicate; the p110 isoform of ADAR1 is an exclusively nuclear protein (1, 9) . The role of p150 in virus infection was independent of the level of virus attenuation, as exemplified by the Edmonston vaccine strain of MV and the wild 5804P strain of CDV that both belong to the Morbillivirus genus. Likewise, the role of p150 was independent of a viral requirement for human SLAM, because similar results were obtained for viruses capable of using hSLAM for cell entry (MV and CDV) and viruses independent of hSLAM (SeV, NDV, and influenza A virus) (21, 22) .
In addition to several genera of the Paramyxoviridae family of viruses, our findings with influenza A virus, a representative member of the Orthomyxoviridae family, show an antiviral role for ADAR1. Not all viruses are inhibited by the p150 isoform of ADAR1, however. We found that p150 deletion did not alter the replication of LCMV, VSV, or reovirus. That replication of some viruses was not changed in the p150 −/− MEFs is not unexpected, given the pleiotropic nature of the IFN response and redundancy of host factors that can affect virus replication (8, 23) . Others have implicated an antiviral function of ADAR1 in infection with the WE strain of LCMV based on mutations observed in the LCMV glycoprotein over time (24) ; however, the respective contributions of p110 and p150 were not examined.
Thus, the IFN-inducible p150 isoform of ADAR1 provides protection against the replication of paramyxoviruses and orthomyxoviruses. It is interesting to note that the representative paramyxovirus and orthomyxovirus family members share a respiratory component for in vivo infection. It is tempting to speculate that the p150 isoform of ADAR1 functions as a host restriction factor of respiratory RNA viruses analogous to the role of the cytidine deaminase APOBEC3G, which exerts its antiviral function by generating hypermutations in the proviral DNA of retroviruses, including HIV (25) (26) (27) (28) . It is possible that extensive hypermutations of the M gene of MV seen in vivo are the result of the known dispensability of the M protein for viral replication (29) , with M gene sequences representing a viral decoy as targets for hypermutation. Significant A-to-G substitutions have also been seen in the viral M gene sequences of influenza A virus recovered from WT animals with intact innate immune responses (30) . A-to-G substitutions in the M gene were reduced in viruses recovered from IKKε-deficient animals with impaired innate immunity (30) . In this animal model, homozygous deletion of the gene encoding the IKKε kinase resulted in hypersusceptibility to influenza A virus infection that correlated with reduced transcriptional up-regulation of several IFNstimulated genes, including ADAR1 in lungs of infected animals (30) . We plan studies to address the function of ADAR1 in vivo as well as the mechanism of p150 action at the molecular level in vitro, including an examination of MV proteins for their ability to antagonize ADAR1 function analogous to the antagonism of ABOBEC3G by the HIV protein Vif (25) (26) (27) (28) .
Materials and Methods
Targeted Disruption of the Gene Encoding the p150 Isoform of ADAR1 and Generation of p150 −/− MEF Cells. To generate a targeting vector for specific disruption of the p150 isoform of ADAR1, genomic sequences encompassing the IFN-inducible P A promoter and associated exon 1A regions were cloned into the pKO-loxP vector (Stratagene). The left arm of the targeting vector contained Adar1 genomic sequence from nucleotides 2,060-6,203, whereas the right arm contained Adar1 genomic sequence from nucleotides 8, 653 . Following electroporation of ES cells of strain 129Sv/Ev and microinjection, chimeric male mice were bred to female C57BL/6J mice. Animals heterozygous for the targeted Adar1 allele were interbred to obtain embryos with both copies of the gene region encoding the p150 isoform of Adar1 deleted. Embryos were collected at E11, E12, and E14, and genomic DNA was isolated for genotyping. MEF cells were derived from embryos at E12, immortalized, and maintained as described below. The following primers were used for genotyping: pADAR1-5902 5′ ATCAGGTACCCAGGGA-TATGGAA 3′, exon 1A PR 5′ AGCAGGGCACTATATACGTTCTCT 3′, and neo-7030 5′ GAACTGTTCGCCAGGCTCAA 3′, with primer pairs pADAR1-5902/ exon1A PR and pADAR1-5902/Neo-7030 detecting the WT and targeted Adar1 alleles, respectively.
Cells and Viruses. MEF cells, either WT, heterozygous, or deficient in the p150 isoform of ADAR1, were maintained in high-glucose DMEM supplemented with 10% (vol/vol) FBS, 2 mM glutamine, 50 μM β-mercaptoethanol, 1 μg/mL doxycycline, penicillin, and streptomycin. The Edmonston vaccine strain of MV, the clone 13 strain of LCMV, the Indiana strain of VSV, and the T3 Dearing strain of reovirus were grown and titered as previously described (31) (32) (33) (34) RNA Isolation and RT-PCR Analysis. RT-PCR analyses of Adar1 transcripts were carried out essentially as described (36) . Total RNA was isolated by the TRIzol method (Invitrogen) following the manufacturer's recommendations. PCR was carried out using random hexamer-primed cDNA and primer pairs specific for mouse Adar1 (36). The forward primer used for the p150 transcript was exon 1A plus 19 corresponding to nucleotides 19-40, and the reverse primer was exon 2 minus 842 corresponding to nucleotides 842-822; for the p110 transcript, the primer pairs were forward exon 1B plus 72 corresponding to nucleotides 72-94 and minus primer 842. Amplification with GAPDH-specific primers as an internal control was as described (37) . IFN treatment was carried out with 1,000 U/mL IFN-αA/D (Pestka Biomedical Laboratories) for 24 h.
Reconstitution of p150 Expression in MEF Cells. The full-length mouse ADAR1 cDNA (accession no. BC042505) in pCMV-SPORT6 (Thermo Fisher Scientific, Inc.) was amplified using the forward primer 5′ CAGTCGGATCCCCACCATG-TCTCAAGGGTTCAGG 3′ with the reverse primer 5′ CATGCTCTCGAGTCA-AGCGTAATCTGGAACATCGTATGGGTAGTCATTGGGTACTGGACA 3′, with the reverse primer designed to introduce an HA epitope tag sequence (underlined) to the 3′ end of the ORF. The ADAR1-HA cDNA was introduced into the lentiviral vector pCSC-SP-PW (38), followed by generation of high-titer lentiviral vector preparations as described (39) . Western blotting of purified vectors using anti-HIV-1 p24 monoclonal antibody 183-H12-5C obtained through the National Institutes of Health AIDS Research and Reference Reagent Program confirmed p24 incorporation equivalent to control lentiviral vectors with a known biological titer of 1 × 10 10 TU/mL. p150 −/− MEF cells stably expressing hSLAM-GFP were transduced twice using 15 and 30 μL of concentrated vector preparations.
Infection of hSLAM-GFP Stable MEF Cells and Plaque Assay. A total of 5 × 10 6 MEF cells stably expressing hSLAM-GFP or GFP were infected in suspension with MV for 2 h at 37°C at an MOI of 0.8 pfu/cell unless otherwise noted. Cells were plated in 24-well plates at 5 × 10 5 cells per well and observed by bright-field microscopy for development of CPE. For plaque assays, both cells and supernatants were harvested, followed by a single freeze-thaw cycle and titration on Vero cells as described (7) . Infections of 1.2 × 10 5 MEF cells with NDV and SeV were carried out at an MOI of 0.1 pfu/cell. Infections with the WSN strain of influenza virus were performed at an MOI of 1.0 pfu/cell, and infections with the wild 5804P strain of CDV were carried out at an MOI of 0.5 50% tissue culture infectious dose per cell.
